HFS Horizons: Life Sciences Service Providers, 2025

The HFS Horizons: Life sciences service providers, 2025 report is for CIOs, chief digital officers, and life sciences transformation leaders evaluating service providers to scale AI across the value chain.

Overview

The HFS Horizons: Life sciences service providers, 2025 report assesses 41 service providers serving the global life sciences industry across pharmaceuticals, biotech, and medical devices, rating each across four dimensions: value proposition (the why), innovation capabilities (the what), go-to-market (the how), and market impact (the so what). The study evaluates providers against the HFS Horizons framework, a three-tier model from HFS Research that measures whether a provider drives operational transformation (Horizon 1), enterprise OneOffice transformation (Horizon 2), or OneEcosystem transformation (Horizon 3), all anchored to the HFS quadruple aim of care: cost, experience, health outcomes, and equity. It concludes that the science is now a given and competition is shifting to the economics of life sciences.

Key findings

1. The report rates 41 service providers and places 8 in Horizon 3 as Market Leaders: Accenture, Deloitte, Brillio, EY, HCLTech, Infosys, TCS, and Wipro.
2. Medicare price negotiations hit 10 drugs from 9 major pharmas starting January 2026, and HFS projects the broader effect to cut pharma revenues by US$1 trillion to US$1.5 trillion over 10 years.
3. The blockbuster era of 1997 to 2024 produced roughly US$2 trillion across about 30 drugs, yet fewer than 10 candidates over the next decade are projected to total only about US$350 billion.
4. Precision-grade therapies have grown 10-fold over 25 years and are projected to reach 50% of all new approvals by 2033.
5. NTT DATA’s Health Data Bank real-world evidence platform spans 140 million patient lives, evidence of named-provider scale across the value chain.

HFS finds that AI, especially GenAI and foundation models, is actively reshaping clinical development, regulatory operations, and commercialization. HFS assesses that providers offering only faster trials and cheaper operations will fall short, and that those expanding access and equity will see outsized impact as revenue headwinds intensify.

The Bottom Line

As life sciences enterprises brace for US$1 trillion to US$1.5 trillion in revenue erosion over the next decade, service providers that move beyond cost and efficiency to deliver measurable outcomes across the quadruple aim of care will earn strategic partner status, while those clinging to legacy outsourcing playbooks will not.

Research methodology

This assessment draws on HFS Pulse demand-side survey data covering roughly 600 enterprises, reference checks with 54 life sciences clients and partners, and detailed briefings with 41 service providers, conducted globally in 2025.

To read the rest of the research, click the download button below.